Association Between Microbiome and the Efficacy and Safety of PD-1/PD-L1 Blockade in Resectable NSCLC

NCT06613308 · clinicaltrials.gov ↗

NOT_YET_RECRUITING

Status

20

Enrollment

OTHER

Sponsor class

Conditions

Lung Cancer (NSCLC)

Interventions

DRUG: Neoadjuvant immunotherapy combined with chemotherapy
DRUG: Neoadjuvant chemotherapy

Sponsor

Capital Medical University

Collaborators

[object Object]